Two former high-level executives of a generic pharmaceutical company have been charged with rigging prices for an antibiotic, the Department of Justice announced.
The charging documents, unsealed in Philadelphia federal court Wednesday, accuse Jeffrey Glazer and Jason Malek of conspiring to fix prices for the antibiotic doxycycline hyclate, rigging bids for the drug and allocating customers. Additionally, authorities claim the pair did them same for glyburide, a diabetes medication.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
